Title : Preparation, characterization, and stability of SubATVax™ adjuvanted commercial veterinary vaccines using six commercial vaccines, including rabies, leptospirosis and an encephalomyelitis combination vaccine for subcutaneous administration
Abstract:
In resource-constrained nations, the cost of commercial vaccines to immunize animals can be prohibitive. For example in the USA the cost of a single dose of rabies vaccine for horses is US $7. The encephalomyelitis combination vaccine for horses is US $28. Various combination vaccines for dairy cows and cattle range from US $5.30-$9.60 per dose. We have recently used our SubATVax™ adjuvant technology, which was originally designed to prepare adjuvants for SARS-CoV-2 spike proteins, to prepare adjuvanted vaccines using commercially available vaccines for horses, dairy cows and cattle, sheep, swine, dogs and cats. Specifically, we have prepared adjuvanted vaccines directed against rabies, leptospirosis, combination products like the Zoetis encephalomyelitis combination vaccine and three other combination vaccines. We will present three-month stability data on the first six commercial animal vaccines encapsulated with our patented SubATVax™ adjuvant, including lazer sizing data, photomicrographs, and video of said adjuvanted vaccines. A demonstration of how veterinarians can encapsulate a vaccine will be performed on a commercial vaccine against rabies. In summary, we have developed a simple method to locally prepare adjuvanted commercial vaccines for subcutaneous administration in mammals. Developing inexpensive adjuvants for approved vaccines, putting multiple vaccine antigens in said adjuvant, decreasing the volume and number of immunizations, and administering these vaccines subcutaneously should allow more animals to be immunized at a fraction of the current cost.
